Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Angew Chem Int Ed Engl ; 60(5): 2588-2593, 2021 Feb 01.
Article in English | MEDLINE | ID: mdl-33051985

ABSTRACT

The coherence time of the 17-electron, mixed sandwich complex [CpTi(cot)], (η8 -cyclooctatetraene)(η5 -cyclopentadienyl)titanium, reaches 34 µs at 4.5 K in a frozen deuterated toluene solution. This is a remarkable coherence time for a highly protonated molecule. The intramolecular distances between the Ti and H atoms provide a good compromise between instantaneous and spin diffusion sources of decoherence. Ab initio calculations at the molecular and crystal packing levels reveal that the characteristic low-energy ring rotations of the sandwich framework do not yield a too detrimental spin-lattice relaxation because of their small spin-phonon coupling. The volatility of [CpTi(cot)] and the accessibility of the semi-occupied, non-bonding d z 2 orbital make this neutral compound an ideal candidate for single-qubit addressing on surface and quantum sensing in combination with scanning probe microscopy.

2.
Drug Discov Today ; 24(11): 2202-2211, 2019 11.
Article in English | MEDLINE | ID: mdl-31539640

ABSTRACT

Parkinson's disease (PD) is a neurodegenerative pathology of the central nervous system, mainly involving the selective and progressive loss of dopaminergic neurons from the substantia nigra, resulting in motor and non-motor symptoms. PD remains an incurable ailment; thus, treatments are limited to symptom alleviation. With long-term use, conventional treatments can become inefficient, often triggering possible side effects. Considering these drawbacks, drug discovery constantly turns to nature as a source of efficient therapeutics. Thus, this review explores animal venoms as a rich source of bioactive compounds with potent neuropharmacological profiles for the development of effective adjuvant treatments with fewer side effects, ultimately aiming for the neuroprotection of dopaminergic neurons and the symptomatic relief of PD.


Subject(s)
Drug Discovery/methods , Neuroprotective Agents/therapeutic use , Parkinson Disease/drug therapy , Venoms/therapeutic use , Animals , Cell Line , Clinical Trials as Topic , Disease Models, Animal , Drug Evaluation, Preclinical , Humans , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/pharmacology , Treatment Outcome , Venoms/administration & dosage , Venoms/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...